Bioxcel forms a Corporate Advisory Board for its next phase of Growth
October 8, 2008 - New Haven, CT. BioXcel Corporation today announced the appointment of three distinguished biopharma executives to its Corporate Advisory Board (CAB). R. Christopher Seaton, SVP of Global Transactions, Bayer Healthcare, Martha Matteo, PhD, Past President of SCIP and recently retired from Boehringer Ingelheim Pharmaceuticals, Inc., where she was the Director for Knowledge Management, and Kevin Rakin, Chairman and CEO of Advanced BioHealing, Inc., are known throughout the biopharma world as outstanding and highly experienced pharmaceutical professionals.
BioXcel, a global, business/IP analytics company, will work closely with these industry leaders to design and develop new strategies for its next phase of corporate growth - targeted to the pharmaceutical, biotechnology, medical device, diagnostic, investment, legal, and related support industries.
“We are delighted to be associated with such a high caliber of experienced pharmaceutical executives," said Vimal D. Mehta, Chairman and co-founder of BioXcel. "Their presence on BioXcel's CAB will assure our planned corporate growth and development at every point in our business model—from assisting clients with R&D services to all the commercial challenges facing today's complex global industries. BioXcel's senior management, executives, and staff join me in welcoming Christopher, Martha, and Kevin to our valued advisor group. With their advice and guidance, BioXcel is now positioned to achieve our next level of planned business growth, maturity, and service capabilities."
BioXcel is delighted to announce our new affiliation with the ASDO Consulting Group. We are now in an unprecedented position to serve the healthcare community from R&D to commercialization and beyond.
June 17, 2008, New Haven, CT. BioXcel Corporation announced a strategic partnership with the ASDO Consulting Group (ASDO), a leading consulting company serving the healthcare industry. BioXcel, a global business analytics company, will combine forces with ASDO’s industry-experienced consultants to expand its repertoire of services. These include business analytics to support licensing/due-diligence, competitive intelligence, IP analytics, and equity research (on-shore/off-shore model). With the ASDO partnership, the combined services will now include corporate and brand strategies, pre/post-launch commercialization solutions including market opportunity assessment, pricing, and reimbursement. Target industries include pharmaceutical, biotechnology, medical device, diagnostic, life science, IP firms, investment banks, and related support industries.
"We are delighted to be working with ASDO," said Krishnan Nandabalan, CEO and co-founder of BioXcel. "The partnership combines our joint expertise into a very broad, significant force in the analytics and commercial marketplace. We can now serve our clients at every point in their business model-from R&D to all the commercial challenges facing today's complex global healthcare industry. This paradigm pioneers a new brand of comprehensive, seamless services that will change the way companies seek expertise, acquire information, and manage resources."
Hovan Asdourian, CEO and Principal Consultant of ASDO, commented, "This is a great synergistic relationship for our two companies. We can now offer clients a comprehensive and integrated set of services from the earliest stages of product discovery and development through all the marketing and commercial aspects that drive corporate strategy and profitability."
BioXcel Corporation's CEO, Dr. Krishnan Nandabalan, was an invited guest speaker at the International Forum on Biotechnology and Pharmacy, Shanghai, May 28-30, 2008.
Nandu spoke on the topic, Fostering Partnership in Biotech and Pharmaceutical Ventures in Asia, in the "Biotechnology Cooperation and Application"session on May 30, 2008.
BioXcel Corporation was present at the JP Morgan Healthcare Conference, 2008.
Vimal Mehta, Chairman, Dr. Krishnan "Nandu" Nandabalan, CEO, and Dr. Matthew Roth, VP-Business Development actively participated in the conference and shared their thoughts with other industry leaders.
